Article Details
Retrieved on: 2024-10-13 01:22:31
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses Alpha Fusion's funding to enhance its development of Astatine-based cancer therapies for global markets, leveraging chemical elements and synthetic elements in targeted alpha-particle therapy, with significant backing from SBI Investment Co. Ltd.
Article found on: www.biospectrumasia.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here